TRCT
IONS icon

Tower Research Capital (TRC)’s Ionis Pharmaceuticals IONS Stock Holding History

Tower Research Capital (TRC)’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335K Buy
4,466
+1,203
+37% +$94.9K 0.01% 1215
2025
Q4 		$258K Buy
3,263
+218
+7% +$16.4K 0.01% 1243
2025
Q3 		$199K Buy
3,045
+1,464
+93% +$71.5K 0.01% 1458
2025
Q2 		$62.5K Sell
1,581
-8,292
-84% -$271K ﹤0.01% 2781
2025
Q1 		$298K Sell
9,873
-4,284
-30% -$140K 0.01% 1144
2024
Q4 		$495K Buy
14,157
+9,856
+229% +$368K 0.01% 1068
2024
Q3 		$172K Sell
4,301
-45,685
-91% -$2.13M ﹤0.01% 1760
2024
Q2 		$2.38M Buy
49,986
+45,123
+928% +$1.85M 0.04% 372
2024
Q1 		$211K Buy
4,863
+1,503
+45% +$71.6K 0.01% 1376
2023
Q4 		$170K Buy
3,360
+2,464
+275% +$118K ﹤0.01% 2233
2023
Q3 		$40.6K Sell
896
-4,992
-85% -$206K ﹤0.01% 2725
2023
Q2 		$242K Sell
5,888
-9,231
-61% -$355K 0.01% 1422
2023
Q1 		$540K Buy
15,119
+7,847
+108% +$295K 0.02% 782
2022
Q4 		$275K Sell
7,272
-4,483
-38% -$189K 0.01% 1083
2022
Q3 		$520K Buy
11,755
+10,325
+722% +$435K 0.01% 1109
2022
Q2 		$53K Sell
1,430
-7,298
-84% -$275K ﹤0.01% 2819
2022
Q1 		$323K Buy
8,728
+7,502
+612% +$246K ﹤0.01% 1436
2021
Q4 		$37K Buy
1,226
+431
+54% +$13.6K ﹤0.01% 3025
2021
Q3 		$27K Sell
795
-9,388
-92% -$354K ﹤0.01% 3456
2021
Q2 		$406K Sell
10,183
-2,140
-17% -$83.8K 0.01% 1346
2021
Q1 		$554K Sell
12,323
-4,620
-27% -$258K 0.01% 1156
2020
Q4 		$958K Sell
16,943
-852
-5% -$42.5K 0.03% 546
2020
Q3 		$844K Buy
17,795
+17,248
+3,153% +$958K 0.01% 1142
2020
Q2 		$33K Sell
547
-6,935
-93% -$386K ﹤0.01% 3381
2020
Q1 		$354K Buy
+7,482
New +$417K 0.02% 553
2019
Q4 		– Sell
-83
Closed -$5K – 3920
2019
Q3 		$5K Sell
83
-1,769
-96% -$115K ﹤0.01% 3306
2019
Q2 		$119K Buy
+1,852
New +$131K 0.01% 1089
2019
Q1 		– Sell
-38
Closed -$2K – 4021
2018
Q4 		$2K Sell
38
-1,767
-98% -$90.1K ﹤0.01% 3374
2018
Q3 		$93K Buy
1,805
+1,075
+147% +$50.5K 0.01% 1390
2018
Q2 		$30K Sell
730
-9,591
-93% -$425K ﹤0.01% 2171
2018
Q1 		$455K Buy
+10,321
New +$524K 0.04% 520
2017
Q3 		– Sell
-677
Closed -$35K – 3959
2017
Q2 		$35K Buy
677
+503
+289% +$23.4K ﹤0.01% 927
2017
Q1 		$7K Sell
174
-1,788
-91% -$80.3K ﹤0.01% 2001
2016
Q4 		$93K Buy
1,962
+1,767
+906% +$69.9K 0.01% 1010
2016
Q3 		$7K Sell
195
-655
-77% -$20.5K ﹤0.01% 2328
2016
Q2 		$20K Buy
850
+809
+1,973% +$26.1K ﹤0.01% 2230
2016
Q1 		$2K Sell
41
-344
-89% -$14K ﹤0.01% 3389
2015
Q4 		$24K Buy
+385
New +$20.8K ﹤0.01% 1102
2015
Q3 		– Sell
-9,265
Closed -$533K – 4362
2015
Q2 		$533K Buy
9,265
+7,568
+446% +$481K 0.05% 134
2015
Q1 		$108K Buy
1,697
+434
+34% +$29.4K 0.01% 817
2014
Q4 		$78K Sell
1,263
-1,875
-60% -$92.5K 0.01% 813
2014
Q3 		$122K Buy
3,138
+3,123
+20,820% +$111K 0.01% 771
2014
Q2 		$1K Sell
15
-2,182
-99% -$68.7K ﹤0.01% 3683
2014
Q1 		$95K Buy
2,197
+883
+67% +$42.8K 0.01% 736
2013
Q4 		$52K Sell
1,314
-7,576
-85% -$270K 0.01% 1356
2013
Q3 		$334K Buy
8,890
+5,389
+154% +$161K 0.04% 465
2013
Q2 		$94K Buy
+3,501
New +$74.4K 0.01% 536

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s IONS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Ionis Pharmaceuticals (IONS) stake by 37% in Q1 2026, buying an estimated $94.9K and bringing the position to 4,466 shares worth $335K. The position accounts for 0.01% of the portfolio, ranked #1215.

Tower Research Capital (TRC) first reported a position in IONS in Q2 2013 and has held it in 47 quarters since. The position peaked at $2.38M in Q2 2024. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Tower Research Capital (TRC) held 4,466 shares of Ionis Pharmaceuticals worth $335K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,203 Ionis Pharmaceuticals shares in Q1 2026, an estimated $94.9K.
  • Ionis Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1215 holding.
  • Tower Research Capital (TRC) first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
  • Tower Research Capital (TRC)'s Ionis Pharmaceuticals position peaked at $2.38M in Q2 2024.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.